Innovations in Biopharmaceutical Treatments

Innovations in Biopharmaceutical Treatments

RELEASE DATE
13-Jul-2018
REGION
Global
Research Code: D951-00-1F-00-00
SKU: CI00543-GL-TA_22116
$950.00
In stock
SKU
CI00543-GL-TA_22116
$950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This Drug Discovery TOE depicts trends across biopharmaceuticals for psoriasis, hepatocellular carcinoma, Crohn's disease, migraine, HIV, and hepatitis B infection, among others. Clinical trial analysis of Etanercept biosimilar is also presented.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Biopharmaceuticals, FDA-approved drugs, psoriasis treatment, Ramucirumab, hepatocellular carcinoma, monoclonal antibody, Crohn’s disease, calcitonin gene-related peptide, drug targets, migraine prevention, multi-drug resistant HIV infection, biologics manufacturing, biosimilar commercialization, X-linked hypophosphatemia, immunotherapy, hepatitis B

Table of Contents

Advancements in Drug Discovery and Development

  • FDA-approved Drug to Provide Affordable Psoriasis Treatment Option
  • Ramucirumab Proves Promising Against Hepatocellular Carcinoma and Bladder Cancer
  • Monoclonal Antibody Targeting Specific Cell Marker in Crohn’s Disease
  • Calcitonin Gene-Related Peptide (CGRP) as a Drug Target for Migraine Prevention
  • Breakthrough Therapy for Multi-drug Resistant HIV Infection
  • Enhancing Biologics Manufacturing Capabilities
  • Accelerating Biosimilar Commercialization
  • Groundbreaking Treatment for X-linked Hypophosphatemia
  • Novel Immunotherapies for Hepatitis B and HIV

Drug Development Analysis and Key Contacts

  • Clinical Trial Analysis of Etanercept Biosimilar
  • Industry Contacts
  • Industry Contacts (continued)
Related Research
This Drug Discovery TOE depicts trends across biopharmaceuticals for psoriasis, hepatocellular carcinoma, Crohn's disease, migraine, HIV, and hepatitis B infection, among others. Clinical trial analysis of Etanercept biosimilar is also presented. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biopharmaceuticals, FDA-approved drugs, psoriasis treatment, Ramucirumab, hepatocellular carcinoma, monoclonal antibody, Crohn’s disease, calcitonin gene-related peptide, drug targets, migraine prevention, multi-drug resistant HIV infection, biologics manufacturing, biosimilar commercialization, X-linked hypophosphatemia, immunotherapy, hepatitis B
More Information
No Index No
Podcast No
Industries Cross Industries
WIP Number D951-00-1F-00-00
Is Prebook No
Ti Codes D904,D913,D91A,D91B,D933,D935,D950